Table 1 Numbers (%) of patients with increases, no change, or decreases from baseline in HDL-C at endpoint presented by treatment group
HDL-C increase and no change | |||
|---|---|---|---|
Treatment Group | HDL-C increase n (%) | No change n (%) | HDL-C decrease n (%) |
PBO (n = 123) | 64 (52.0) | 4 (3.3) | 55 (44.7) |
FENO (n = 368) | 309 (84.0) | 8 (2.2) | 51 (13.9) |
EZE+FENO (n = 183) | 163 (89.1) | 3 (1.6) | 17 (9.3) |
EZE/SIMVA+FENO (n = 180) | 161 (89.4) | 3 (1.7) | 16 (8.9) |